All lobbying filings
DENDREON PHARMACEUTICALS, LLC
DENDREON PHARMACEUTICALS, LLC filed a Q3 report for DENDREON PHARMACEUTICALS, LLC on December 2, 2025.
Lobbying for DENDREON PHARMACEUTICALS, LLC
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Dec 2, 2025
Expenses
$59,650
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
2
Lobbying activity
1
Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.